Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG110A in NDO-related Incontinence Following SCI
NCT06596291Phase 2Recruiting
- Sponsor
- Cyllene Therapeutics
- Start
- Jan 2025
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, Herpes Simplex Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of EG110A in neurogenic detrusor overactivity (NDO), sponsored by Cyllene Therapeutics. Started Jan 2025; status: recruiting.
02
Drugs
EG110A
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT06596291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06596291.